COMPUTATIONAL STUDY OF BUTYL AND NAPHTHYL AMINE DERIVATIVE OF PERYLENE DIIMIDES TARGETTING TELOMERASE ENZYME FOR ANTICANCER ACTIVITY by Cn, Hemalatha & M, Vijey Aanandhi
Vol 11, Special issue 4, 2018
Online - 2455-3891 
Print - 0974-2441
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11s4.31679
COMPUTATIONAL STUDY OF BUTYL AND NAPHTHYL AMINE DERIVATIVE OF PERYLENE 
DIIMIDES TARGETTING TELOMERASE ENZYME FOR ANTICANCER ACTIVITY
HEMALATHA CN, VIJEY AANANDHI M*
Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and 
Advanced Studies, Pallavaram, Chennai, Tamil Nadu, India. Email: hodpchemistry@velsuniv.ac.in
Received: 10 October 2018, Revised and Accepted: 11 December 2018
ABSTRACT
Objective: Telomeres are protective caps present at the end of the chromosomes and it contains genetic information. From the literature survey, 
we selected perylene diimides which interact with the telomerase enzyme and possess anticancer activity. Telomestatin a macrocyclic chemical 
compound that inhibits telomerase activity as well it induces the formation of G-Quadruplex structures in the telomeric region. The main objective 
of the study was to find the binding affinity of butyl and naphthyl amine derivative of perylene ligands targeting telomerase enzyme for anticancer 
activity. Telomerase enzyme is responsible for maintaining the length of telomeres and keeping the chromosomes intact longer. Telomeres will 
become increasingly common with age. Perylene diimides and its derivatives show good biological activity and also in vitro studies possess efficient 
anticancer agent. The butyl and naphthyl amine derivatives are screened by computational techniques to study regarding binding energy and ligand 
interactions with respect to the targets.
Methods: Butyl and naphthyl amine derivative of perylene diimides is drawn using Accelrys Draw. The structures are retrieved from the previous 
study. The structures are converted to pdb formats using Discovery Studio Visualizer 4.1. The study was to investigate the binding energy values of 
butyl and naphthyl amine derivatives of perylene diimides. Auto Dock 4.2 was used to dock the ligand with the targets. The target selected for docking 
was 3CE5 and 4B18. The results are visualized by Discovery Studio Visualizer 4.1. The results are compared with the standard drug N,N’-bis-(2-(1-
piperidino)ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide (PIPER).
Results: From the results, butylamine derivative of perylene diimide possesses good binding energy when compared with standard drug PIPER. This 
result shows that the butylamine will be effective for anticancer therapy. In future, in vivo studies of butylamine derivative of perylene diimide will be 
carried out.
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INTRODUCTION
Perylene moiety is basically used for the dye and the rigid macromolecular 
structure helps to intercalate the G-quadruplex to inhibition of 
telomere [1,2]. The perylene pigments are solid and these pigments 
have received considerable attention in academic as well industrial 
dye research. At the perylene core, different kinds of substituent can 
be introduced and the position or the nature of the substituent should 
be a strong impact on pharmacokinetic and pharmacologic properties 
[3,4]. In the Bay region, amine groups can be substituted and primary 
or secondary amine or modified substituent’s can be attached at the R2 
position. In this study, docking has been done using AutoDock 4.2. The 
target selected for this study was a telomerase protein (3CE5 and 4B18-
PDB ID), and using this as target, we studied and docked the butyl and 
naphthyl amine derivative of perylene diimide compounds [5].
METHODS
AutoDock 4.2
Molecular docking was performed by the AutoDock 4.2 Tools. It helps 
to understand the binding properties in a steady-state environment. In 
this study, we used 3CE5 and 4B18-a telomerase protein.
The calculations of AutoDock are done in several steps: Respective files 
for the docking analysis have been prepared and saved in coordinate 
formats. The second step was to calculate the atomic affinities required 
for the Auto Grid. Finally, the ligands are docked using Auto Dock. The 
results are analyzed using tools of Auto Dock and the interactions are 
visualized using Discovery Studio Visualizer 4.1 [6].
Preparation of ligands for docking
Perylene diimide ligands were drawn using Accelrys Draw. The 
structures are converted from two-dimensional to three dimensional 
(3D) using discovery studio visualizer 4.1. and saved as.pdb format.
Preparation of protein (3CE5 and 4B18)
The crystallographic structures which are retrieved from RCSB–Protein 
Data Bank should be in high resolution (www.rcsb.org). The binding 
selectivity with respect to the protein environment was essential to 
understand the biological activity of a drug molecule as prototype 
therapeutic agent. Docking study was performed to understand and 
correlate their biological efficacy toward the selected binding domain of 
the protein. We used the AutoDock 4.2 MGL tools version 1.5.6 software 
packages for the molecular docking experiment and Discovery Studio 
Visualizer to visualize the results.
The deletion of the both water molecules and the inorganic charges 
was done to avoid error. Lamarckian genetic algorithm was applied to 
identify the binding site. Molecular docking analysis was done by the 
output file of the docking that was generated after the study.
The binding energy, inhibition constant, and the number of hydrogen 
bonds were considered for the analysis. Butylamine derivative 
of perylene diimide showed potent binding interactions with the 
proteins 3CE5 and 4B18 and compared with the standard N,N’-bis-
(2-(1-piperidino)ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide 
(PIPER) [7,8]. The structures of novel butyl and naphthalene perylene 
diimide derivatives along with the IUPAC are tabulated in Table 1.
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The binding energy values are showing equivalent potent values 
when compared with the standard PIPER. The binding energy values 
for the compound - butylamine derivatives of Perylene diimide - were 
−9.67 (3CE5) and −5.33 (4B18) and for the PIPER were −10.46 (3CE5) 
and −5.59 (4B18) kcal/mol, respectively.
PIPER the standard compound was drawn using Accelrys Draw and 
converted to 3D structure, saved in.pdb format. The perylene derivatives 
and PIPER are computed for docking with the two selected targets 
(3CE5 and 4B18) to compare and to study the ligand interactions and 
binding energy.
The two compounds of butyl and naphthyl amine derivatives of perylene 
diimides are docked with the two targets (3CE5 and 4B18) and compared 
with the PIPER compound. The results are tabulated in Table 2. Among 
the two perylene compounds, butylamine derivative of perylene diimide 
possesses good binding energy when compared with the PIPER compound 
which shows that these compounds possess highest binding affinities and 
these compounds are tabulated and represented in graph chart in Fig. 1.
The hydrogen bond interactions with the enzyme and the ligand are 
screened using Discovery Studio 4.1 Visualizer and are tabulated in 
Tables 3 and 4.
Table 1: Structure of novel butyl and naphthyl perylene diimides
SL. No. Structure IUPAC name
R1 5,12-bis (bis (2-hydroxyethyl) amino)-2,9-dihexylanthra[2,1,9-def: 6,5,10-d’e’f ’]
diisoquinoline-1,3,8,10 (2H,9H)-tetraone




PIPER: N, N’-bis-(2-(1-piperidino) ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide
Fig. 1: Results of perylene diimides derivatives with the standard 
compound N,N’-bis-(2-(1-piperidino)ethyl)-3,4,9,10-perylene 
tetracarboxylic acid diimide - binding energy (kcal/mol)
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RESULTS
Docking has been done by AutoDock 4.2. After selecting the 
macromolecule, grid will be generated and saved as.pdbqt format. 
Once the AutoGrid was generated, docking parameters are carried out 
using the parameters [9,10]. AutoDock job was done, and the results 
will be in the format of Complex.pdb files (protein-ligand bound file) 
and are visualized by Discovery Studio Visualizer 4.1 Visualizer. From 
the results, butylamine perylene diimide derivative shows good binding 
energy value when compared with the standard drug PIPER [11].
DISCUSSION
From the docking results, butylamine perylene diimide derivative 
showed good inhibitory constant value and good binding energy which 
possesses a good correlation coefficient [12-15]. The interactions with 
the protein and the ligand show the ligand binds with the protein and 
Table 2: Docking results of butyl and naphthyl amine derivatives of perylene diimides
Compounds Target PDBs - telomerase inhibitors
3CE5 4B18
Butylamine perylene diimide
Binding energies −9.65 −5.33
Inhibition constant (µM) 83.72 nM 122.99 µM




Naphthyl amine perylene diimide
Binding energies −8.69 −6.23
Inhibition constant (µM) 424.94 µM 26.99 µM
Hydrogen bond contact Nil 11th: 0:O18
4B18:B: LYS236:N 
PIPER
Binding energies −10.46 −5.59
Inhibition constant (µM) 21.69 nM 80.55 µM





PIPER: N, N’-bis-(2-(1-piperidino) ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide
Table 3: Hydrogen bond interactions with the enzyme and the ligands - 3CE5
S. No. Compound 3CE5
1. Butylamine perylene diimide - R1
2. Naphthyl Amine- Perylene diimide - R2
3. PIPER
PIPER: N, N’-bis-(2-(1-piperidino) ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide
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ensure that perylene derivatives are having strong affinity with the 
targets (3CE5 and 4B18).
CONCLUSION
From the results, the best compound, butylamine perylene diimide 
derivative will be highly efficient by targeting the telomerase enzyme, 
and the compound can be used further for in vivo studies which will be 
effective for anticancer therapy [16-18]. The interactions show that the 
affinity toward the targets was effective when compared with the PIPER 
ligand. The butylamine perylene diimide derivative can be taken as a 
Scaffold for further synthetic work and these derivatives have a scope 
and potential for anticancer activity with respect to the telomerase 
enzymes.
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